Generic Name and Formulations:
Poractant alfa (as phospholipids 80mg/mL and proteins 1mg/mL); susp for intratracheal administration; preservative-free.
Chiesi USA, Inc.
Indications for CUROSURF:
Treatment ("rescue") of respiratory distress syndrome (RDS) in premature infants.
See literature. Give by intratracheal administration through an endotracheal tube. Each dose should be administered as 2 aliquots. Inital dose of 2.5mL/kg birth weight; may give 2 more doses of 1.25mL/kg birth weight at 12-hour intervals.
Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully.
Bradycardia, hypotension, reflux of surfactant into endotracheal tube, others.
Single-use vials (1.5mL, 3mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma